US 12,448,455 B2
Combination therapies with bispecific anti-EGFR/c-met antibodies and third generation EGFR tyrosine kinase inhibitors
Sylvie Laquerre, Chesterbrook, PA (US); Matthew Lorenzi, Philadelphia, PA (US); and Sheri Moores, Wayne, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed on Nov. 15, 2023, as Appl. No. 18/510,412.
Application 18/510,412 is a division of application No. 15/931,726, filed on May 14, 2020, granted, now 11,879,013.
Claims priority of provisional application 62/847,563, filed on May 14, 2019.
Claims priority of provisional application 62/847,605, filed on May 14, 2019.
Prior Publication US 2024/0199748 A1, Jun. 20, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 31/5377 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 31/5377 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01)] 23 Claims
 
1. A pharmaceutical combination comprising:
a therapeutically effective amount of an isolated bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody; and
a therapeutically effective amount of a compound of formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or hydrate thereof,
wherein the isolated bispecific EGFR/c-Met antibody comprises:
(a) a first domain that binds EGFR, the first domain comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; and
(b) a second domain that binds c-Met, the second domain comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO: 7, a HCDR2 comprising the amino acid sequence of SEO ID NO: 8, a HCDR3 comprising the amino acid sequence of SEO ID NO: 9, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 10, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 12.